One study suggested that a combination of anti-PD-L1 and anti-TGF-ß1 therapies may overcome immunotherapy resistance, as TGF-β forms a tumor microenvironment to inhibit anti-tumor immunity by restricting T-cell infiltration (Mariathasan et al. 2018). The gene discussed is TGFB1; the disease is neoplasm.